Inflammation and Benign Prostatic Hyperplasia

Overview

Journal Urol Clin North Am

Specialty Urology

Date 2007 Dec 7

PMID 18061029

Citations 52

Authors

J Curtis Nickel

Affiliations

Soon will be listed here.

Abstract

Prostatitis, a histologic diagnosis, has evolved over the years to describe a clinical syndrome that was believed to be associated with prostatic inflammation. Similarly, benign prostatic hyperplasia (BPH), another histologic diagnosis, has evolved to describe a clinical syndrome believed to be associated with prostatic enlargement. Recent explorations of the interrelationships between these prostate-associated histologic and clinical conditions have generated much interest and excitement. This article describes these relationships and their impact on the management of, in particular, BPH.

Citing Articles

Exploration of diagnostic biomarkers, microenvironment characteristics, and ursolic acid's therapeutic effect for benign prostate hyperplasia.

Chen Y, Xu H, Xu H, Liu C, Zhan M, Wang Z Int J Biol Sci. 2023; 19(13):4242-4258.

PMID: 37705744 PMC: 10496513. DOI: 10.7150/ijbs.85739.

Mechanism of Androgen-Independent Stromal Proliferation in Benign Prostatic Hyperplasia.

Hata J, Harigane Y, Matsuoka K, Akaihata H, Yaginuma K, Meguro S Int J Mol Sci. 2023; 24(14).

PMID: 37511400 PMC: 10380833. DOI: 10.3390/ijms241411634.

Primary bladder neck obstruction in men-new perspectives in physiopathology.

Cash H, Wendler J, Minore A, Kartalas Goumas I, Cindolo L Prostate Cancer Prostatic Dis. 2023; 27(1):54-57.

PMID: 37422524 PMC: 10876476. DOI: 10.1038/s41391-023-00691-1.

Increased COX-1 expression in benign prostate epithelial cells is triggered by mitochondrial dysfunction.

Hudson C, He K, Pascal L, Liu T, Myklebust L, Dhir R Am J Clin Exp Urol. 2022; 10(4):234-245.

PMID: 36051613 PMC: 9428567.

Applications of Vertebrate Models in Studying Prostatitis and Inflammation-Associated Prostatic Diseases.

Bleeker J, Wang Z Front Mol Biosci. 2022; 9:898871.

PMID: 35865005 PMC: 9294738. DOI: 10.3389/fmolb.2022.898871.

References

Buck A . Is there a scientific basis for the therapeutic effects of serenoa repens in benign prostatic hyperplasia? Mechanisms of action. J Urol. 2004; 172(5 Pt 1):1792-9. DOI: 10.1097/01.ju.0000140503.11467.8e. View

Untergasser G, Madersbacher S, Berger P . Benign prostatic hyperplasia: age-related tissue-remodeling. Exp Gerontol. 2005; 40(3):121-8. DOI: 10.1016/j.exger.2004.12.008. View

Collins M, Stafford R, OLeary M, Barry M . Distinguishing chronic prostatitis and benign prostatic hyperplasia symptoms: results of a national survey of physician visits. Urology. 1999; 53(5):921-5. DOI: 10.1016/s0090-4295(98)00636-0. View

Theyer G, Kramer G, Assmann I, Sherwood E, Preinfalk W, Marberger M . Phenotypic characterization of infiltrating leukocytes in benign prostatic hyperplasia. Lab Invest. 1992; 66(1):96-107. View

Kohnen P, Drach G . Patterns of inflammation in prostatic hyperplasia: a histologic and bacteriologic study. J Urol. 1979; 121(6):755-60. DOI: 10.1016/s0022-5347(17)56980-3. View

Kakehi Y, Segawa T, Wu X, Kulkarni P, Dhir R, Getzenberg R . Down-regulation of macrophage inhibitory cytokine-1/prostate derived factor in benign prostatic hyperplasia. Prostate. 2004; 59(4):351-6. DOI: 10.1002/pros.10365. View

Nickel J, Roehrborn C, OLeary M, Bostwick D, Somerville M, Rittmaster R . The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial. Eur Urol. 2007; 54(6):1379-84. PMC: 2643127. DOI: 10.1016/j.eururo.2007.11.026. View

Nickel J, Downey J, Young I, Boag S . Asymptomatic inflammation and/or infection in benign prostatic hyperplasia. BJU Int. 1999; 84(9):976-81. DOI: 10.1046/j.1464-410x.1999.00352.x. View

Kramer G, Marberger M . Could inflammation be a key component in the progression of benign prostatic hyperplasia?. Curr Opin Urol. 2005; 16(1):25-9. View

10.

Konig J, Senge T, Allhoff E, Konig W . Analysis of the inflammatory network in benign prostate hyperplasia and prostate cancer. Prostate. 2004; 58(2):121-9. DOI: 10.1002/pros.10317. View

11.

St Sauver J, Jacobson D, McGree M, Girman C, Lieber M, Jacobsen S . Longitudinal association between prostatitis and development of benign prostatic hyperplasia. Urology. 2008; 71(3):475-9. PMC: 2597174. DOI: 10.1016/j.urology.2007.11.155. View

12.

Nickel J, Roehrborn C, OLeary M, Bostwick D, Somerville M, Rittmaster R . Examination of the relationship between symptoms of prostatitis and histological inflammation: baseline data from the REDUCE chemoprevention trial. J Urol. 2007; 178(3 Pt 1):896-900. DOI: 10.1016/j.juro.2007.05.041. View

13.

Nickel J, True L, Krieger J, Berger R, Boag A, Young I . Consensus development of a histopathological classification system for chronic prostatic inflammation. BJU Int. 2001; 87(9):797-805. DOI: 10.1046/j.1464-410x.2001.02193.x. View

14.

Pontari M . Chronic prostatitis/chronic pelvic pain syndrome in elderly men: toward better understanding and treatment. Drugs Aging. 2003; 20(15):1111-25. DOI: 10.2165/00002512-200320150-00004. View

15.

True L, Berger R, Rothman I, Ross S, Krieger J . Prostate histopathology and the chronic prostatitis/chronic pelvic pain syndrome: a prospective biopsy study. J Urol. 1999; 162(6):2014-8. DOI: 10.1016/S0022-5347(05)68090-1. View

16.

Minnery C, Getzenberg R . Benign prostatic hyperplasia cell line viability and modulation of jm-27 by doxazosin and Ibuprofen. J Urol. 2005; 174(1):375-9. DOI: 10.1097/01.ju.0000161598.24740.34. View

17.

Steiner G, Gessl A, Kramer G, Schollhammer A, FORSTER O, Marberger M . Phenotype and function of peripheral and prostatic lymphocytes in patients with benign prostatic hyperplasia. J Urol. 1994; 151(2):480-4. DOI: 10.1016/s0022-5347(17)34998-4. View

18.

Brookes S, Donovan J, Peters T, Abrams P, Neal D . Sexual dysfunction in men after treatment for lower urinary tract symptoms: evidence from randomised controlled trial. BMJ. 2002; 324(7345):1059-61. PMC: 104331. DOI: 10.1136/bmj.324.7345.1059. View

19.

Di Silverio F, Bosman C, Salvatori M, Albanesi L, Pannunzi L, Ciccariello M . Combination therapy with rofecoxib and finasteride in the treatment of men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH). Eur Urol. 2004; 47(1):72-8. DOI: 10.1016/j.eururo.2004.08.024. View

20.

Merendino R, Salvo F, Saija A, Di Pasquale G, Tomaino A, Minciullo P . Malondialdehyde in benign prostate hypertrophy: a useful marker?. Mediators Inflamm. 2003; 12(2):127-8. PMC: 1781597. DOI: 10.1080/0962935031000097745. View